Health care resources available for medical procedures, including pharmaceuticals, are limited worldwide. Health economic evidence is now accepted as an essential component of health technology appraisal, realizing the importance of value for money considerations for a more efficient (cost-effective) prescribing. Regulatory agencies in more and more countries perform economic evaluation and cost-effectiveness analysis in order to decide about reimbursement of a new and almost always more expensive drug. Pharmacoeconomy is now acknowledged as a science. Cost-effective analysis is just one of its approaches, measuring cost in money and benefit in terms of Quality Adjusted Life Year, a new outcome measure which combines quantity/quality of additional life-years gained with the new drug/technology. A growing body of pharmacoeconomic evidence about new anticoagulant drugs (dabigatran, rivaroxaban, apixaban) for stroke prevention in atrial fibrillation is now available. Most of this evidence comes from the National Institute of Health and Clinical Excellence (NICE) in the United Kingdom, the most referenced regulatory agency in the world. Compared to current standard therapies (warfarin), dabigatran, rivaroxaban and apixaban are cost-effective treatments for the whole population of patients with atrial fibrillation, independently of poor/good international normalized ratio control (time in therapeutic range) and risk stratification for stroke (CHADS2 score). Significant innovation and the lower rate of intracranial hemorrhage/hemorrhagic stroke coupled with the new drugs are the key drivers of these results.
Introduction
Worldwide, warfarin is one of the most prescribed drugs. The main indication for oral anticoagulant therapy is atrial fibrillation (AF). Given the high prevalence of AF in older individuals and the aging population an ever-increasing number of people are expected to start warfarin. The drawbacks in its use are well known and are well reviewed elsewhere in this journal. 1 Dabigatran, rivaroxaban and apixaban are new anticoagulant drugs with the potential of replacing oral anticoagulant therapy, as clearly demonstrated by several randomized controlled trials (RCT).
Substituting a new anticoagulant for warfarin will result in an additional burden to the pharmacy budget for anticoagulation therapy due to the increased drug costs. 2 The current acquisition cost of a new anticoagulant drug is 2-3 euros/day versus 0.07 euros/day for warfarin. Such a policy for the entire Italian AF population (650,000 patients) would result in an incremental cost of 0.5 billion euros. The importance of an evidence based health policy has now been acknowledged worldwide, given the limited healthcare resources available. Reimbursement of new medicines is subjected to economic evaluation to improve efficient allocation of public resources. 3, 4 Cost-effectiveness analysis Briefly, economic evaluation is a formal comparison of alternative actions in terms of costs and benefits. Cost-effectiveness analysis (CEA) is one of the four types of full economic evaluation (Table 1) in which costs are measured in monetary terms and outcomes are measured using a common unit of effect. 3 This common unit is a clinical measurement when evaluating alternatives that produce the same effect (e.g. anti-hypertensive drugs and mm Hg values reduction in blood pressure). If the alternatives do produce multiple effects, a more general measure is needed. This measure is the Quality Adjusted Life Year (QALY): CEA is also Review known as cost-utility analysis, when QALY is used to measure effectiveness. The QALY combines and weighs quantitative and qualitative data about life improvements, where 1 is the weight of full health and 0 is the weight of dead-equivalent. [3] [4] [5] Various methods for determining weights are available; of course, CEA including these methods are considered superior to others that do not. 6, 7 Cost-effectiveness analysis considers all the costs associated with a new technology/drug, not merely acquisition costs. Costs and savings accruing on the patients, their families and even the impact upon economic activities, have to be considered. Again, methods for these types of evaluation are well established. 3 There are several different approaches to assess cost-effectiveness according to the data collection methods used (Table 2 ). CEA can be conducted alongside RCTs that provide evidence for efficacy and safety of a new technology/drug. This approach, often called piggy-back analysis, has several drawbacks that limit its application. These include: limited time-horizon, selected patient populations, economic data/analysis conducted for registration, not for pharmacoeconomic purposes. Economic modeling on the basis of the results of RCTs is perhaps the most accepted approach by decision makers to substantiate a reimbursement decision on a new drug; the decision tree, Markov and discrete event simulation are the most frequently applied. Clinical data from RCT are put together with information from epidemiological and cost-of-illness studies and other retrospective data sources, thus allowing a longer time horizon, and re- 
New anticoagulant drugs versus warfarin in atrial fibrillation
sults that can be generalized and adjusted to local medical practice and patient population. The level of appropriateness of modeling assumptions (i.e. model structure, time horizon, sophistication of the model to differentiate clinically and economically meaningful outcomes) is of paramount importance in determining accuracy of CEA estimates. Input parameters are subject to considerable uncertainty both qualitatively and quantitatively, thus making conclusions less clear. [3] [4] [5] Once the costs (money) and effects (QALY) of a new technology/drug have been established, they have to be paired with a comparator, usually the current gold standard in order to calculate the incremental cost effectiveness ratio (ICER). The ICER is calculated by dividing the difference in the expected costs by the difference in the expected QALY (Figure 1 ). This acquisition is very important from the perspective of a decision maker, because a threshold (i.e. maximum ICER value) could be established in order to accept/reject reimbursement for a new drug. [3] [4] [5] The World Health Organization developed the CHOICE project (choosing interventions that are cost-effective) with the objective of providing policy makers with the evidence needed to allow them to decide on the interventions and programs which maximize health for the available resources. 8 CHOICE uses gross domestic product (GDP) as a readily available indicator from which to derive the following three categories of costeffectiveness: i) highly cost-effective (<GDP per capita); ii) cost-effective (1-3 times GDP per capita); and iii) not cost-effective (>3 times GDP per capita).
The National Institute of Health and Clinical Excellence (NICE) in the United Kingdom is perhaps the most famous regulatory agency dealing with decision making to accept or refuse to make new drugs available on the market based on CEA. When a NICE technology appraisal recommends use of a drug, treatment or other technology, the UK National Health Service must usually provide funding and resources for it within three months of the guidance being published.
NICE uses a standard approach to calculate cost and benefits: medicines whose ICER fall below the range of £20,000-30,000 per QALY gained are more likely to be approved than medicines whose ICER exceeds this national threshold. Nevertheless, the decisions of NICE are not wholly related to this unique parameter. Special circumstances if applicable, are considered and medicines with threshold-exceeding ICER are sometimes approved. [9] [10] [11] Such special circumstances could include severity of underlying illness, end-of-life treatments, stakeholder pressure, significant innovation, disadvantaged population, or children.
New anticoagulant drugs: economic evaluation
Emerging health-economic evidence is available in the literature about new anticoagulant drugs. Most of this evidence is related to dabigatran, the first drug to generate evidence and to be introduced on the market.
Dabigatran
The most extensive and accurate CEA for dabigatran versus warfarin in AF has been produced by 2012 NICE technology appraisal document, on the basis of RELY trial results. 12 The committee concluded that the most plausible ICERs for the whole population eligible for dabigatran were within the range normally considered a cost-effective use of National Health Service resources, i.e. less than £20,000 per QALY gained. Apart from this, some comments must be made about a number of controversial issues. 
12
Dabigatran CEA in AF have been conducted in other countries by local health services. Three studies demonstrated the cost-effectiveness of abigatran across the USA. Freeman and Homan yielded an ICER less than 50,000 US dollars (USA ICER threshold) in the whole AF population and in patients with previous stroke/transient ischemic attack, respectively, while Shah documented a cost effectiveness only in people at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent. From the perspective of Canadian Health Services, dabigatran versus warfarin is cost-effective with an ICER of 10,440 Can dollars/QALY.
Cost-effectiveness analyses have also been conducted across the European Union. According to national health services, dabigatran is considered cost-effective versus warfarin in AF patients in Belgium, Denmark, Sweden, UK and Spain. A recent paper extends the same results to Switzerland [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ( Table 3) .
Rivaroxaban
Evidence from the ROCKET trial was the basis for a NICE technology appraisal document on rivaroxaban. 24 The most plausible ICER for rivaroxaban versus warfarin lies between £2870 and £29,500 per QALY gained, given that the principle driver of CEA and the main source of uncertainty was the cost of anticoagulation monitoring. However, this ICER value is not above the threshold of £30,000 and rivaroxaban is considered a cost-effective option in AF patient management in the UK.
No clinically relevant subgroups for which there is evidence of differential effectiveness were identified. Rivaroxaban is a cost-effective treatment for the whole population of patients with AF, independently of risk stratification (CHADS2 score) and poor/good INR control (TTR).
Rivaroxaban has been evaluated for cost-effective- 
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ness from the perspective of the US health services. The ICER for rivaroxaban was $27,498 per QALY, well below the US-ICER threshold of $50,000 per QALY. Again, the major driver of CEA was the lower hazard of intracranial hemorrhage with rivaroxaban.
25

Apixaban
Very recently, NICE evaluated apixaban for costeffectiveness on the data from the ARISTOTLE randomized clinical trial. 26 The same standard approach used for dabigatran and rivaroxaban appraisal was used. The Committee concluded that apixaban had been shown to be cost-effective compared with warfarin, the most plausible ICER being less than £20,000 per QALY gained. Again, apixaban is a recommended option for the whole AF population, independently of CHADS2 score and TTR.
A comment was made about the different calculated ICERs for new anticoagulants. The ICER for apixaban was lower than that for dabigatran that was in turn lower than that for rivaroxaban, giving rise to the possibility of a different cost effectiveness among the drugs. There is, however, considerable uncertainty about the relative treatment effects of the drugs, arising from the base-line characteristics of people included in the trials and no firm conclusion can really be drawn on this issue. The Committee concluded that, for the moment, there was insufficient evidence to distinguish between the cost effectiveness of apixaban, dabigatran and rivaroxaban.
Conclusions
Economic evaluation and CEA conducted in European and North American countries have demonstrated the cost effectiveness of dabigatran, rivaroxaban and apixaban compared to warfarin for stroke prevention, in atrial fibrillation. In other words, the expected benefits, progressively increasing over time, far outweigh the higher initial acquisition cost. From the perspective of a regulatory agency, responsible for reimbursement of the cost of the drug, the number of patients subjected to treatment is of paramount importance for cost estimation. While no restriction to subgroup is applied to the population of patients with AF in Europe, Canada or the US, in Italy, the national local regulatory agency (Agenzia Italiana del Farmaco, AIFA) has still not made such a decision. 
